MedPath

Study of Atropine Therapeutic Effect on Myopic Progression

Phase 3
Recruiting
Conditions
Children
Myopia
Interventions
Registration Number
NCT05529056
Lead Sponsor
LitePharmTech Co., Ltd.
Brief Summary

This study is to evaluate the therapeutic effect and safety of LPTAT in children with myopia.

Detailed Description

The primary objective is to evaluate the superiority of LPTAT to placebo in slowing myopia progression through the change of SE(Spherical Equivalent), which is measured by cycloplegic autorefraction after 12-month treatment.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
472
Inclusion Criteria
  • Aged 5 to 12 years at the time of consent
  • Refractive error of SE at least -1.0 D and no greater than -8.0 D in both eyes as measured by cycloplegic autorefraction at visit 1 and visit 2.
  • Confirmed myopia progression of 0.5D or more within past 1year
  • Astigmatism of 2.5D or less in both eyes
  • Distance Best Corrective Visual Acuity to logMAR 0.2 or better in both eyes at visit1.
  • Normal IOP under 21mmHg in both eyes.
  • Anisometropia of SE less than 2.0D as measured by cycloplegic autorefraction at visit 1.
  • Written informed consent willingly obtained by both subject and his/her parents
Exclusion Criteria
  • Hypersensitivity to atropine or other cycloplegic agent.
  • History of the surgery of refractive correction
  • Having ocular disease affect to visual function or refractive error: history of glaucoma, macula r degeneration, diabetic eye disease, uveitis, etc, or presence of conjunctivitis at screening visit.
  • Having systemic diseases that affect to vision loss
  • Having risk of IOP elevation such as narrow angle, Shallow Anterior Chambers, etc
  • Presence of binocular function disorder or stereopsis disorder
  • Amblyopia or manifest strabismus
  • History of premature birth(less than 37weeks) or low birth weight(less than 2,500g)
  • Previous or current use of atropine or Ortho-K lens for myopia
  • Down syndrome, spastic paralysis, brain damage, spastic palsy, bladder
  • Presence of neurological diseases like epilepsy, etc. which could expect difficulties in compliant to the ocular examinations.
  • Presence of clinically significant cardiac and respiratory diseases
  • Participation in any other clinical study of an investigational product within 3-month prior to current IP administration.
  • Based on the investigator's discretion, subject who is not proper to participate in the trial.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Test Arm 1Atropine Sulfate 01LPTAT01
Test Arm 2Atropine Sulfate 02LPTAT02
Test Arm 3Atropine Sulfate 03LPTAT03
Reference ArmPlaceboLPTAT04
Primary Outcome Measures
NameTimeMethod
Change in Spherical Equivalent over 12-month12 months

Change in spherical equivalent measured by cycloplegic autorefraction at 12 months after administration of clinical trial drug compared to baseline

Secondary Outcome Measures
NameTimeMethod
Change in Spherical Equivalent4, 8 months

Change in spherical equivalent measured by cycloplegic autorefraction at 4, 8 months after administration of clinical trial drug compared to baseline

Change in Axial length (mm)4, 8, 12 months

Change in Axial length (mm) at 4, 8, 12 months after administration of clinical trial drug compared to baseline

Trial Locations

Locations (15)

Chung-Ang University Gwang Myeong hospital

🇰🇷

Gwangmyeong, Korea, Republic of

Chungnam National University Hospital

🇰🇷

Daejeon, Korea, Republic of

The Catholic University of Korea Seoul St. Mary's Hospital

🇰🇷

Seoul, Korea, Republic of

Yongin Severance Hospital

🇰🇷

Yongin, Korea, Republic of

Pusan National University Hospital

🇰🇷

Busan, Korea, Republic of

Gachon University Gil Hospital

🇰🇷

Incheon, Korea, Republic of

HanGil Eye Hospital

🇰🇷

Incheon, Korea, Republic of

Inje University Busan Paik Hospital

🇰🇷

Busan, Korea, Republic of

Seoul Asan Medical Center

🇰🇷

Seoul, Korea, Republic of

Kangwon National University Hospital

🇰🇷

Chuncheon, Korea, Republic of

Ajou University Hospital

🇰🇷

Suwon, Korea, Republic of

Seoul National University Bundang Hospital

🇰🇷

Seongnam-si, Korea, Republic of

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

Samsung Medical Center

🇰🇷

Seoul, Korea, Republic of

Kim'S Eye Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath